Time points | Study period | ||||
---|---|---|---|---|---|
Allocation | Post-allocation | ||||
t1pre | t1 | t1post | t2 | t3 | |
ENROLMENT | |||||
Eligibility screena | ✓ | ||||
Informed consent | ✓ | ||||
Randomized assignment | ✓ | ||||
INTERVENTIONS | |||||
Nocebo-education group | ✓ | ||||
Attention control group | ✓ | ||||
ASSESSMENTS | |||||
Baseline variables | |||||
Demographic and medical characteristics | ✓ | ||||
Distress Thermometer | ✓ | ||||
Information coping style | ✓ | ✓ | |||
Outcome variables | |||||
Side effect number and intensity (GASE)b | ✓ | ✓ | |||
Coping with side effects (GASE-Coping) | ✓ | ✓ | |||
Misattribution of symptoms (GASE-Attribution) | ✓ | ✓ | |||
Co-medication to treat side effects (yes/no) | ✓ | ✓ | |||
Compliance intention | ✓ | ✓ | ✓ | ✓ | |
Attitude towards the chemotherapy | ✓ | ✓ | ✓ | ✓ | |
Severity of toxicity (CTC)c | ✓ | ✓ | ✓ | ||
Further variables | |||||
Expected side effects (GASE-Expect) | ✓ | ✓ | |||
Expected coping with side effects (GASE-Coping Expect) | ✓ | ✓ | |||
Expected efficacy of chemotherapy | ✓ | ||||
Relevance of the conversation | ✓ | ||||
Knowledge about the nocebo effectd | ✓ | ✓ | ✓ | ||
Disease progression | ✓ | ✓ |